#]

8	نسا	8	_
	8		

AMENDMENT NO	Calendar No	
--------------	-------------	--

Purpose: To change conditions of first generic exclusivity to spur access and competition.

IN THE SENATE OF THE UNITED STATES—116th Cong., 1st Sess.

S. 1895				
To lower health care costs.				
Referred to the Committee on and ordered to be printed				
Ordered to lie on the table and to be printed				
Amendment intended to be proposed by Mr. Scott of South Carolina				
Viz:				
1 Strike section 205 and insert the following:				
2 SEC. 205. CHANGE CONDITIONS OF FIRST GENERIC EXCLU				
3 SIVITY TO SPUR ACCESS AND COMPETITION				
4 (a) IN GENERAL.—Section 505(j)(5)(B)(iv) of the				
5 Federal Food, Drug, and Cosmetic Act (21 U.S.C				
6 355(j)(5)(B)(iv)) is amended—				
7 (1) in subclause (I) by striking "180 days after				
8 the date" and inserting "180 days after the earlier				
9 of the following:				
10 "(aa) "The date"; and				
11 (2) by adding at the end the following:				

1.	"(bb) The date on which all
2	of the following conditions are
3	first met:
4	"(AA) An application
5	for the drug submitted by
6	an applicant other than a
7	first applicant could receive
8	approval, if no first appli-
9	cant were eligible for 180-
10	day exclusivity under this
11	clause.
12	"(BB) Thirty months
13	have passed since the date
14	of submission of an applica-
15	tion for the drug by at least
16	one first applicant.
17	"(CC) Approval of an
18	application for the drug sub-
19	mitted by at least one first
20	applicant is not precluded
21	under clause (iii).
22	"(DD) No application
23	for the drug submitted by
24	any first applicant is ap-
25	proved at the time the con-

1	ditions under items (AA),
2	(BB), and (CC) are all met,
3	regardless of whether such
4	an application is subse-
5	quently approved."; and
6	(3) by adding at the end the following:
7	"(III) EXCEPTION.—
8	"(aa) In GENERAL.—The
9	date in paragraph (I)(bb) shall
10	not apply if In the case that any
11	first applicant is actively pur-
12	suing final approval of an appli-
13	cation for the relevant drug, then
14	the applicable date under sub-
15	clause (I) shall be the date de-
16	scribed in item (aa).
17	"(bb) Definition.—For the
18	purposes of this subclause, the
19	term 'actively pursuing final ap-
20	proval' means an applicant's
21	good faith effort to pursue mar-
22	keting approval in a timely man-
23	ner, based on a consideration of
24	all relevant factors, such as the
25	applicant's compliance with regu-

4

1	lations and the timeliness of its
2	responses to the Secretary's
3	questions or application defi-
4	ciencies during the review pe-
5	riod.".